MedTrace Logo

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

NCT00977561 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2013-02-25

Study results available
· View outcomes & findings →

Summary

This study will summarize the safety of patients receiving figitumumab combined with etoposide and cisplatin (or carboplatin) vs. patients receiving etoposide and cisplatin (or carboplatin) alone as first line treatment for extensive stage disease Small Cell Lung Cancer.

Conditions

  • Small Cell Lung Carcinoma

Interventions

DRUG

figitumumab

Figitumumab (20 mg/kg)

DRUG

Cisplatin (Or Carboplatin)

Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5

DRUG

Etoposide

Etoposide (100 mg/m2 IV on Days 1, 2 and 3)

DRUG

Cisplatin (Or Carboplatin)

Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5

DRUG

Etoposide

Etoposide (100 mg/m2 IV on Days 1, 2 and 3)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States
  • Canada
  • Hungary
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00977561 on ClinicalTrials.gov